Human Rejuvenation Treatment to Begin First Human Trials
Boston, MA – Life Biosciences, a Boston-based startup cofounded by Harvard professor David Sinclair, received FDA approval to begin the first human trials of its rejuvenation treatment, codenamed ER-100, according to MIT Technology Review. The announcement followed a brief exchange on X between Sinclair and Elon Musk at Davos, where Musk speculated that aging is "very solvable" and that the reason for aging will be "something obvious." Sinclair responded to Musk, stating that aging has a "relatively simple explanation and is apparently reversible."
ER-100 is a targeted treatment designed to reverse aspects of aging. While specific details of the treatment remain undisclosed, the upcoming clinical trials mark a significant step forward in the field of life extension research. Sinclair, a prominent figure in the field, has long advocated for the reversibility of aging.
The trials are scheduled to begin "shortly," according to MIT Technology Review. The company has not released further details regarding the trial's design, participant selection, or expected timeline.
Discussion
Join the conversation
Be the first to comment